Hepatitis A Virus

Slide 1 · Hepatitis A Virus

Transmission • immune-mediated injury • clinical course • diagnosis

Pathology teaching lecture

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Identify the virologic characteristics and fecal–oral transmission of HAV.

Trace infection, host immunity, hepatocyte injury, and clinical evolution.

Interpret acute versus previous infection using anti-HAV IgM and IgG.

Recognize unusual complications and explain why chronic HAV does not occur.

Apply prevention and clinicopathologic reasoning to short clinical scenarios.

Slide 3 · HAV within the spectrum of viral hepatitis

Hepatotropic viruses A–E share liver tropism but differ in transmission and persistence.

HAV typically causes an acute, self-limited hepatitic illness.

Unlike HBV and HCV, HAV does not produce chronic hepatitis or a carrier state.

Clinical and histologic features alone cannot reliably specify the virus.

Slide 4 · Virologic identity of hepatitis A

Small, nonenveloped, positive-sense single-stranded RNA virus.

Belongs to the picornavirus family, genus Hepatovirus.

Icosahedral capsid; A diameter of approximately 27 nm.

These structural features describe the pathogen—not the mechanism of hepatocyte death.

Slide 5 · Virion organization: Conceptual model

Nonenveloped capsid

Positive-sense ssRNA genome

Picornaviridae • Hepatovirus

~27 nm (Robbins)

Original conceptual virion schematic, not an electron micrograph

Slide 6 · Why HAV belongs in acute hepatitis

Fecal–oral exposure

Hepatocyte infection

Immune injury

Recovery

Virus enters the host by an exposure route linked to fecal contamination.

Infection reaches hepatocytes and provokes an antiviral immune response.

The immune response causes transient hepatocellular injury.

Viral clearance is ordinarily followed by recovery and lasting immunity.

Slide 7 · Contrast with other hepatotropic viruses

Feature

HAV

HBV / HCV

HEV

Typical route

Fecal–oral

Primarily parenteral / blood-related

Fecal–oral

Persistent infection

No chronic hepatitis

Chronic disease can occur

Chronicity possible in immunocompromised hosts

Key teaching point

Acute illness with immunity

Important chronic liver diseases

Acute disease; special host risks

Slide 8 · The defining natural-history distinction

HAV infection is self-limited in nearly all patients.

It does not establish a persistent carrier reservoir.

Prolonged symptoms or a relapse are not equivalent to chronic viral infection.

That distinction changes diagnostic counseling and long-term risk assessment.

Slide 9 · The fecal–oral route

Infected host

Stool shedding

Contaminated vehicle

New ingestion

Virus shed in stool contaminates food, water, hands, or the immediate environment.

Ingestion introduces HAV to a susceptible individual.

Close contact and contaminated common sources both support transmission.

This is the core epidemiologic mechanism.

Slide 10 · Why sanitation matters

HAV is endemic where sanitation and hygiene are inadequate.

Contaminated water and food are important transmission vehicles.

Environmental conditions that permit fecal contamination amplify outbreaks.

Improved sanitation reduces opportunities for exposure.

Slide 11 · Timing of fecal shedding

Jaundice begins

Approximate interval of stool shedding

2–3 weeks before onset

~1 week after onset

Transmission can therefore precede recognition of a symptomatic case.

Absence of visible icterus does not imply absence of infectious exposure.

Timing is from the Robbins HAV section; Not to quantitative scale

Slide 12 · Why cases transmit before diagnosis

Peak infectivity in acute viral hepatitis may overlap late incubation and early symptoms.

A presymptomatic person may contaminate shared environments.

Contact tracing based only on the day jaundice appears can miss earlier exposure.

A transmission history must look backward into the incubation period.

Slide 13 · Close personal contact as an exposure

Close contact with an infected individual is a major epidemiologic setting.

Repeated opportunities for fecal–oral contamination enable person-to-person spread.

Clusters may develop before the first recognized patient becomes jaundiced.

Slide 14 · Institutional outbreaks

Schools and nurseries as potential outbreak settings.

Shared facilities and close contact support multiple linked exposures.

An outbreak investigation should consider shared food, water, and contact networks.

The relevant transmission mode remains fecal–oral.

Slide 15 · Water-associated epidemics

Contaminated water can lead to epidemic transmission.

Overcrowding and unsanitary conditions increase the risk.

A shared water source may expose many susceptible hosts simultaneously.

Epidemic clustering differs from independent sporadic infections.

Slide 16 · Shellfish as a foodborne vehicle

Human sewage

Contaminated seawater

Shellfish concentration

Consumption

Raw or lightly cooked oysters, mussels, and clams are highlighted.

Shellfish can concentrate viruses from sewage-contaminated seawater.

Consumption may produce sporadic infections even in high-income countries.

The exposure links marine contamination to human fecal waste.

Slide 17 · Sexual and blood-borne transmission

Sexual transmission can occur, particularly with fecal–oral exposure.

Viremia is transient, making blood-borne transmission rare.

Donated blood is not routinely screened for HAV.

These less-common pathways do not displace fecal–oral spread as the dominant route.

Slide 18 · Maternal–fetal transmission

No maternal–fetal transmission for HAV.

This contrasts with the clinically important perinatal routes of some other hepatitis viruses.

Do not extrapolate the transmission characteristics of HBV to HAV.

Slide 19 · Seroprevalence reflects past exposure

Anti-HAV seropositivity may indicate previous infection or immunity.

In high-resource settings, historical exposure typically increases with age.

Robbins provides age-related US seroprevalence as an epidemiologic example.

Seropositivity alone does not establish a current symptomatic illness.

Slide 20 · Epidemiology is time- and setting-dependent

HAV as an important cause of clinically evident acute hepatitis.

The textbook also records an increase in reported US cases in its source context.

Case counts and exposure patterns can change with outbreaks, immunity, and sanitation.

Historical figures must not be presented as real-time surveillance data.

Slide 21 · HAV pathogenesis in four linked events

Infection

Antiviral recognition

Hepatocyte injury

Regeneration

Host exposure is followed by hepatocyte infection.

Antiviral lymphocytes recognize infected cells.

Cytotoxic effector mechanisms injure the liver.

Resolution follows immune control and hepatocyte regeneration.

Slide 22 · A receptor identified

Hepatocyte HAVcr-1, also called TIM-1.

TIM-1 is a glycoprotein discussed in relation to entry by multiple viruses.

Receptor biology is distinct from the immune-mediated injury mechanism.

This is a textbook statement, not an independently updated receptor review.

Slide 23 · HAV is not directly cytopathic

Robbins explicitly describes HAV as noncytopathic.

The predominant mechanism of hepatocellular injury is antiviral immune attack.

Infected hepatocytes can be killed by cytotoxic T lymphocytes and NK cells.

Thus, tissue injury reflects host–virus interaction rather than direct lysis by HAV.

Slide 24 · Cellular immune effectors

Cytotoxic T lymphocytes recognize and eliminate infected hepatocytes.

Natural killer cells also participate in killing infected cells.

This response reduces infected-cell burden but produces hepatocellular damage.

Inflammatory recruitment accompanies the injured liver parenchyma.

Slide 25 · Immune-mediated hepatocyte injury

Infectedhepatocyte

CytotoxicT lymphocyte

NK cell

Immune recognition and killing

Schematic: Immune effector cells are shown apart from tissue architecture

HAV itself is described as noncytopathic.

Slide 26 · Necrosis and apoptosis are different

Necrosis

Apoptosis

Cell swelling

Membrane disruption

Cellular-content release

Cell shrinkage

Nuclear condensation

Acidophilic body formation

Interpretive comparison: Terminology differs by clinical context

Slide 27 · Acute hepatitis: Portal and lobular inflammation

Acute viral hepatitis can show inflammation within portal tracts and lobules.

The infiltrate is predominantly lymphocytic.

Plasma cells and eosinophils may be present in variable numbers.

This pattern overlaps with several nonviral inflammatory liver diseases.

Slide 28 · The hepatic lobule as an injury map

Central vein

Portal tracts at lobular periphery

Schematic classical lobule; Not histologic image or diagnostic micrograph

Slide 29 · Apoptotic hepatocytes: Acidophil bodies

Apoptotic hepatocytes appear shrunken and deeply eosinophilic.

Chromatin condensation and cell fragmentation accompany apoptosis.

“acidophil bodies” for apoptosis in hepatitis.

The eponym “Councilman bodies” is reserved by convention for yellow fever.

Slide 30 · Macrophages clear injured parenchyma

Macrophages phagocytose debris from necrotic hepatocytes.

Pigmented macrophages may mark prior sites of hepatocyte death.

Lobular inflammation and phagocytic clearance are linked processes.

These changes are not specific for HAV.

Slide 31 · Severe acute injury: Confluent necrosis

Confluent necrosis is loss of contiguous groups of hepatocytes.

Bridging necrosis can connect vascular structures.

Panacinar necrosis may obliterate an entire lobule.

Extensive cell loss can progress to massive hepatic necrosis and liver failure.

Slide 32 · Morphologic severity spectrum

Focal apoptosis

Lobular necrosis

Confluent loss

Massive necrosis

The same acute disease framework can span limited hepatocyte apoptosis to extensive dropout.

Severe necrosis reduces functioning liver mass.

Morphologic severity and clinical liver failure are related but not interchangeable.

Slide 33 · Why histology cannot type hepatitis A

Acute hepatitic patterns are shared across hepatotropic viruses.

Drug reactions, autoimmune hepatitis, and Wilson disease can overlap morphologically.

Etiologic typing therefore requires appropriate serologic or molecular testing.

A biopsy may assess injury, but HAV is not diagnosed by a unique H&E signature.

Slide 34 · Chronic hepatitis morphology is a contrast, not HAV evolution

Acute HAV

Chronic viral hepatitis

Time-limited inflammatory injury

Recovery expected

No chronic carrier state

Persistent inflammation

Fibrosis may accumulate

HBV/HCV are major causes

Interpretive comparison: Terminology differs by clinical context

Slide 35 · The four clinical phases of acute hepatitis

Incubation

Preicteric

Icteric

Convalescence

Incubation precedes obvious illness.

A symptomatic preicteric interval can follow.

Icteric symptoms may then become apparent.

Convalescence follows as the liver injury resolves.

Slide 36 · Incubation: 2–6 weeks

The source gives a 2–6-week incubation period for HAV.

The patient may appear well while infection develops.

Exposure inquiry must include the weeks before symptom onset.

A remembered meal or contact immediately before jaundice may be unrelated.

Slide 37 · Subclinical infection is possible

Acute hepatitis can occur without overt symptoms.

A clinically silent episode may be recognized later by antiviral antibodies.

The absence of jaundice is not evidence against prior HAV exposure.

Symptom-based surveillance can therefore miss infections.

Slide 38 · The preicteric presentation

Fatigue and appetite loss are prominent nonspecific symptoms.

These complaints alone cannot establish an etiologic diagnosis.

A relevant exposure history and hepatitis testing guide recognition.

This phase may precede visible jaundice.

Slide 39 · Icteric presentation

Patients often develop jaundice during symptomatic acute infection.

Icterus reflects accumulation of bilirubin.

Recognition of jaundice occurs after part of the stool-shedding interval.

Clinical severity requires evaluation beyond the presence of yellow discoloration.

Slide 40 · Jaundice links function to appearance

Altered bile handling can cause bilirubin retention.

Bilirubin accumulation produces yellow skin and scleral discoloration.

A prolonged cholestatic course is an uncommon HAV complication.

Icterus alone does not establish acute liver failure.

Slide 41 · Usual time to recovery

Most patients recover within 3 months.

Nearly all have resolution by 6 months.

Recovery represents clearance of the acute infection.

This timeline is consistent with the absence of chronic HAV infection.

Slide 42 · Course of illness and immune markers

Incubation

Symptoms begin

Recovery

Long term

IgM anti-HAV

Detected from onset; Persists 3–6 months

IgG anti-HAV

Appears during recovery; Persists for years

IgM suggests recent infection; IgG reflects durable immune memory.

Slide 43 · IgM anti-HAV identifies a recent response

IgM anti-HAV appears at the onset of symptoms.

Persistence for approximately 3–6 months.

IgM positivity supports a recent/acute HAV infection in the appropriate setting.

The test result should be interpreted in the clinical context.

Slide 44 · IgG anti-HAV marks durable immunity

IgG anti-HAV appears during recovery.

It persists for years and confers long-term immunity.

IgG positivity without evidence of an acute IgM response favors prior immune exposure.

Antibodies after vaccination may also signify immunity.

Slide 45 · Anti-HAV results: Practical interpretation

IgM anti-HAV

IgG anti-HAV

Interpretive principle

Positive

May be positive

Recent infection likely with compatible clinical context

Negative

Positive

Prior infection / immunity, not proof of acute HAV

Negative

Negative

No anti-HAV serologic evidence of previous exposure

Any discordance

Any discordance

Review timing, exposure, and clinical course

Slide 46 · A focused diagnostic reasoning sequence

Clinical suspicion

Exposure review

Anti-HAV serology

Integrated diagnosis

Identify acute hepatitic symptoms and relevant epidemiologic exposure.

Use anti-HAV IgM to evaluate suspected recent HAV infection.

Interpret anti-HAV IgG as evidence of prior immune response.

Consider alternative causes when the presentation or test pattern is discordant.

Slide 47 · Why laboratory and morphology must agree

H&E inflammatory patterns overlap across different causes of hepatitis.

IgM and IgG reflect infection timing and host immune response.

Clinical course provides an independent consistency check.

Discordant information should prompt reassessment rather than forced attribution.

Slide 48 · Acute liver failure is uncommon but important

Acute liver failure in 0.1%–0.3% of HAV infections.

This event is uncommon relative to uncomplicated recovery.

An otherwise self-limited virus can still cause life-threatening acute hepatic injury.

The low frequency must not lead to dismissal of rapidly worsening symptoms.

Slide 49 · Chronic liver disease increases vulnerability

The source particularly notes acute liver failure in patients with liver disease of another cause.

Reduced hepatic reserve may increase consequences of an acute insult.

HAV does not need to become chronic to worsen preexisting chronic liver disease.

Clinical interpretation must distinguish baseline disease from the acute superimposed infection.

Slide 50 · What constitutes acute liver failure?

A syndrome of encephalopathy and coagulopathy after acute liver injury.

definition, onset is within 26 weeks and without preexisting liver disease.

A patient with preexisting chronic liver disease requires different syndrome classification.

Neither isolated jaundice nor isolated transaminase elevation is sufficient.

Slide 51 · Failure of synthesis and detoxification

Massive cell loss

Synthetic failure

Metabolic failure

Clinical deterioration

Reduced coagulation-factor synthesis contributes to coagulopathy.

Failure to detoxify ammonia contributes to encephalopathy.

Massive hepatocyte loss may cause multiorgan complications.

Assessment of function matters more than transaminase magnitude alone.

Slide 52 · A dangerous laboratory paradox

In severe liver failure, transaminases can fall as viable hepatocyte mass is lost.

Worsening jaundice, coagulopathy, or encephalopathy despite falling enzymes is alarming.

A falling enzyme level cannot be equated automatically with recovery.

This principle follows the general acute liver failure discussion.

Slide 53 · Prolonged cholestasis after HAV

Some patients have a prolonged cholestatic course.

Cholestasis denotes impaired bile formation or flow with retained solutes.

Persistence of jaundice in this setting does not prove chronic HAV infection.

Serial assessment should distinguish prolonged recovery from liver failure.

Slide 54 · Relapsing disease after initial improvement

Relapses within 6 months of the original onset.

Relapse represents renewed clinical activity during an acute disease course.

It is not equivalent to a stable chronic carrier state.

A renewed episode should still be assessed for alternative causes.

Slide 55 · Extrahepatic manifestations: The overview

Rash and arthralgia can accompany HAV infection.

Immune-complex mechanisms are invoked in rare systemic complications.

The organ systems involved may include skin, kidney, and vessels.

Extrahepatic manifestations do not establish chronic viral persistence.

Slide 56 · Immune-complex associated manifestations

HAV immune response

Immune complexes

Vascular / renal effects

Schematic causal overview; No disease-specific microscopic specimen depicted

Leukocytoclastic vasculitis is listed among the possible manifestations.

Glomerulonephritis can represent renal involvement.

Cryoglobulinemia is another reported immune-complex phenomenon.

These are uncommon and require diagnostic evaluation in context.

Slide 57 · Typical and atypical outcomes

Acute HAV infection

Usual recovery + IgG immunity

Uncommon cholestasis / relapse

Rare acute liver failure

No chronic HAV hepatitis or persistent carrier state

Slide 58 · Why HAV does not create a carrier state

The virus is cleared rather than maintained as a persistent transmissible infection.

IgG anti-HAV remains after recovery even when acute infection has resolved.

The host may be antibody-positive without continuing to harbor HAV.

Never equate seropositivity with infective carriage.

Slide 59 · Vaccination interrupts the susceptible-host pathway

HAV vaccination is effective in preventing infection.

Vaccine-derived immunity reduces the population of susceptible hosts.

Vaccination is complementary to sanitation and exposure prevention.

Specific schedules and postexposure protocols are beyond the supplied Robbins excerpt.

Slide 60 · Prevention targets the exposure chain

Sanitation

Food / water safety

Contact precautions

Immunity

Protect food and water from fecal contamination.

Reduce close-contact transmission through hygienic practices.

Consider implicated shellfish and environmental sources during investigations.

Vaccination reduces susceptibility before exposure.

Slide 61 · Case 1: Jaundice after a shared meal

Clinical reasoning exercise

An adult reports fatigue and anorexia, then jaundice several weeks after eating shellfish with a group.

Which exposure feature raises concern for HAV?

Which antibody class best supports a recent infection?

Why might other exposed persons remain asymptomatic at first?

Slide 62 · Case 1: Interpret the evidence

Shellfish may concentrate HAV from contaminated seawater.

IgM anti-HAV supports recent infection in the appropriate context.

The 2–6-week incubation explains a delayed symptomatic presentation.

Subclinical infection and presymptomatic shedding complicate outbreak detection.

Slide 63 · Case 2: Recurrent jaundice without chronicity

Clinical reasoning exercise

A patient improves after acute HAV and experiences recurrent symptoms months later.

Relapse within 6 months as an uncommon outcome.

Why should this not automatically be labeled chronic hepatitis A?

What further evaluation is needed if the course is clinically discordant?

Slide 64 · Case 3: Deteriorating liver function

Clinical reasoning exercise

A patient with acute hepatitis develops confusion and a prolonged coagulation test.

Which clinical syndrome must be considered urgently?

Would falling transaminases independently indicate recovery?

Which underlying-liver-disease history would alter the syndrome classification?

Slide 65 · Case 3: Clinicopathologic interpretation

Encephalopathy and coagulopathy are features of acute liver failure.

Extensive hepatocyte necrosis can reduce functional liver mass.

Falling transaminases may coexist with worsening liver failure.

Preexisting liver disease changes formal classification and clinical reserve.

Slide 66 · Integrated concept: HAV infection in one pathway

Exposure

Immune hepatitis

Acute IgM response

Immune recovery

Transmission is predominantly fecal–oral, with shedding before jaundice.

HAV-infected hepatocytes are injured by cytotoxic immune cells.

Symptoms and IgM antibody characterize the acute period.

Recovery brings IgG-associated immunity; Chronic hepatitis does not develop.

Slide 67 · Five decisions to remember

Is the exposure compatible with fecal–oral transmission?

Is the illness acute, and does IgM anti-HAV support it?

Is the patient improving or showing functional deterioration?

Could cholestasis, relapse, or immune-complex disease explain atypical findings?

Has immunity and prevention been addressed?

Slide 68 · Textbook references

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th edition. Elsevier.

Primary textbook section: Hepatitis A Virus; background section: Viral Hepatitis.

Additional context: Clinicopathologic Syndromes of Viral Hepatitis; Hepatocyte and Parenchymal Responses; Acute Liver Failure.

All schematics were newly constructed as editable teaching diagrams; no textbook figures are reproduced.